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Myotonic dystrophy type 1 (DM1) lacks non-invasive and easy to measure biomarkers, still largely relying on semi-quantitative tests
for diagnostic and prognostic purposes. Muscle biopsies provide valuable data, but their use is limited by their invasiveness. microRNA
(miRNAs) are small non-coding RNAs regulating gene expression that are also present in biological ﬂuids and may serve as diseases
biomarkers. Thus, we tested plasma miRNAs in the blood of 36 DM1 patients and 36 controls. First, a wide miRNA panel was
proﬁled in a patient subset, followed by validation using all recruited subjects. We identiﬁed a signature of nine deregulated miRNAs
in DM1 patients: eight miRNAs were increased (miR-133a, miR-193b, miR-191, miR-140-3p, miR-454, miR-574, miR-885-5p,
miR-886-3p) and one (miR-27b) was decreased. Next, the levels of these miRNAs were used to calculate a “DM1-miRNAs score”.
We found that both miR-133a levels and DM1-miRNAs score discriminated DM1 from controls signiﬁcantly and Receiver–Operator
Characteristic curves displayed an area under the curve of 0.94 and 0.97, respectively. Interestingly, both miR-133a levels and
DM1-miRNAs score displayed an inverse correlation with skeletal muscle strength and displayed higher values in more compromised
patients.
In conclusion, we identiﬁed a characteristic plasma miRNA signature of DM1. Although preliminary, this study indicates miRNAs as
potential DM1 humoral biomarkers.
 2014 The Authors. Published by Elsevier B.V.
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Myotonic dystrophy (DM) is the most common type of
muscular dystrophy in adults characterized by muscle
weakness, myotonia and multisystemic features, like
cardiac and central nervous system involvement [1].
Indeed, after respiratory failure, cardiac arrhythmias arehttp://dx.doi.org/10.1016/j.nmd.2014.02.005
0960-8966  2014 The Authors. Published by Elsevier B.V.
⇑ Corresponding author. Address: Molecular Cardiology Laboratory,
IRCCS-Policlinico San Donato, 20097 San Donato Milanese, Milan,
Italy. Tel.: +39 0252774533.
E-mail address: fabio.martelli@grupposandonato.it (F. Martelli).
Open access underthe second most frequent death cause for DM patients
[1]. The most common and severe form of DM is named
type 1 or Steinert’s disease (DM1, OMIM 160900) and is
caused by (CTG)n expansions in the 3
0untranslated region
of the DMPK gene [2].
The main analytical methods for DM1 diagnosis and
prognosis are based on muscle biopsy immunohistochemistry,
electromyography, and DNA mutation analysis [1]. Albeit
very informative, the invasive nature of muscle biopsy analysis
precludes its repeated use to monitor disease progression and
therapy eﬃcacy. Another important limitation is the
variability between diﬀerent skeletal muscles, that allows the CC BY-NC-ND license.
Table 1
DM1 patient clinical characteristics (n = 36).
Age (years ± se)
(Range)
42.2 ± 2.4
(17–72)
Sex (male/female) 18/18
Skeletal muscle strength (MRC megascore, max 150,
mean ± se)
128.0 ± 2.9
Myotonia (%) 100
Glucose (mg/dL, normal values 70–110 mg/dL,
mean ± se)
77.6 ± 1.9
Insulin resistance (%) 38.5
CPK (mg/dL, normal range, m < 190, f < 167 mg/dl,
mean ± se)
Males:
307.8 ± 59.7
Females:
187.9 ± 34.6
Calcium (mg/dL, normal values 8.60–10.20 mg/dL,
mean ± se)
9.3 ± 0.1
Stage of disease (MIRS) (range 1–5%) Stage 2: 15.6
Stage 3: 28.1
Stage 4: 56.3
Arrhythmia (%) 46.9
Cataract (%) 36.8
ECG–QRS duration (ms, normal range 60–100 ms,
mean ± se)
104.6 ± 5.4
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muscle. Manual (MMT) and quantitative (QMT) muscle test
are useful instrument in clinical practice, but require trained
personnel and are prone to high variability between operators.
Indeed, standard protocols have not yet deﬁned [3]. Also
magnetic resonance imaging is very useful for DM patient
care, but it incurs in high costs and requires specialized
personnel and protocols to provide quantitative data [4,5].
Among analytical measurements of humoral markers, CK
activity is seldom used in clinical settings since it lacks disease
speciﬁcity and it is not always increased in DM1 patients [6].
Thus, the identiﬁcation of a minimally invasive analytical
biomarker correlating with disease conditions is a clearly
unmet need for DM1 care.
microRNAs (miRNAs) are small non-coding RNA
modulating gene expression at post-transcriptional level
[7] and their expression and intracellular distribution is
deregulated in many human diseases, including muscular
dystrophies [8–11]. Interestingly, Chen et al.
demonstrated that miRNAs derived from various tissues
and organs are easily detectable in both plasma and
serum, being stable and resistant to nuclease digestion
[12]. In addition, serum/plasma levels of miRNAs have
been found to be reproducible and indicative of the
disease state [12] also in mouse models and in patients
aﬀected by Duchenne muscle dystrophy and limb-girdle
muscular dystrophy type 2C and 2D [13–15]. Given the
lack of humoral biomarkers for DM1 and the established
potential of circulating miRNAs as prognostic and
diagnostic biomarkers, we proﬁled miRNAs in plasma of
DM1 patients.
2. Materials and methods
2.1. Patients selection and plasma collection
This study was authorized by the Institutional Ethics
Committee (Azienda Sanitaria Locale Milano 2) and was
conducted according to the principles expressed in the
Declaration of Helsinki, the institutional regulation and
Italian laws and guidelines. All blood samplings were
taken after speciﬁc written informed consent. Clinical
diagnosis of DM1 patients was based upon International
Consortium for myotonic dystrophies guidelines [16] and
genetic analysis was carried out to conﬁrm DM1
diagnosis, as previously described [17–19]. Stage of
disease was determined using Muscular Impairment
Rating Scale (MIRS) [20]: 1 = no muscular impairment
(controls), 2 = minimal signs, 3 = distal weakness,
4 = mild–moderate proximal weakness, 5 = severe
proximal weakness. Five-point MRC scale (Medical
Research Council) in the upper and lower limbs for a
total maximum score of 150 (MRC megascore) was used
to evaluated muscle strength [21]. Speciﬁcally, the score
was obtained measuring on both sides 7 muscle groups of
the upper limbs (shoulder abductors and adductors,
elbow ﬂexors and extensors, wrist ﬂexors and extensors,ﬁnger ﬂexors) and 7 muscle groups of the lower limbs
(hip ﬂexors and extensors, knee ﬂexors and extensors,
ankle dorsiﬂexors and plantar ﬂexors, extensor hallucis)
as well as neck ﬂexors and extensors. Myotonia was
evaluated qualitatively during neurological examination
and conﬁrmed by needle electromyography. To test
insulin resistance, HOMA-IR score was calculated from
fasting glucose and insulin level. A score >2.6 is
considered as insulin resistance.
Blood samples were obtained by venous punctures of 36
DM1 (Table 1) patients and of 36 sex and age matched
subjects displaying no sign of neuromuscular disorders
(47.6 ± 2.3 years old, range 25–76 years, 20 females and
16 males). EDTA-tubes were used for plasma
preparation. Cell- and platelet-free plasma was prepared
following a 2 step centrifugation protocol: samples were
centrifuged at 1.500 g for 150 at 4 C. Next, the
supernatant was centrifuged again at 14.000 g for 150 at
4 C and stored at 80 C [22].2.2. RNA isolation
Total RNA was extracted from plasma using
NucleoSpin miRNA Plasma (Macherey-Nagel) according
to the manufacturer’s instructions. Brieﬂy, 0.3 ml of
plasma were used for total RNA extraction and
25 fmoles of cel-miR-39 synthetic spike-in (mirVana
miRNA Mimic, Life technologies) were added before
protein precipitation step. Pellets were resuspended in
50 ll of RNAse-free water. NanoDrop (Thermo
Scientiﬁc) spectrophotometer quantiﬁcation was not
reliable, likely because of the very low amount of RNA
yielded. Thus, cel-miR-39 was measured by quantitative
PCR (qPCR) to assess the eﬃciency of extraction.
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Fig. 1. Validation of miRNAs modulation in plasmas of DM1 patients.
The bar graph represents mean values of the indicated miRNAs in
plasmas of DM1 patients compared to CTR (DM1 n = 36, CTR n = 36,
*p < 0.05, **p < 0.01, ****p < 0.0001).
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TaqMan Human MicroRNA A Array version 3.0
(Applied Biosystems) was used for miRNA expression
screening of 381 miRNAs. Reverse transcription (RT)
was performed using 3 ll of total RNA and card A
Megaplex RT primers (10), according to the
manufacturer instructions. Then, 2.5 ll of cDNA were
pre-ampliﬁed. Finally, each sample was uploaded in each
card and 50 cycles qPCR were performed using a 7900
HT Fast-Real Time PCR apparatus (Applied Biosystem).
After median Ct values normalization, relative miRNA
expression was calculated with the DDCt method as
previously described [9]. In order to validate proﬁling
data, we ﬁltered raw data (Table S1) for those miRNAs
with a Ct 6 30 and a signiﬁcant DDCtP |1|. Single
TaqMan microRNA assays were performed according to
the manufacturer instruction (Applied Biosystems) and
cel-miR-39, miR-17-5p and miR-106a were used as
normalizers. Intra-assay variability for detection of
individual miRNAs is indicated in Table S2. For the
“DM1-miRNAs score” calculation, the module of the
fold changes obtained for all validated miRNAs was
averaged.
2.4. Statistical analysis
Continuous variables are expressed as mean ± standard
error (SE) unless indicated diﬀerently. For group-wise
comparisons, Mann–Whitney test or t-test were used as
appropriate. The ability to discriminate between the
DM1 and control groups was characterized by the
receiver operating characteristic curve, and the area
under the curve (AUC) was calculated. A ROC curve
allows to visualize the reciprocal relationship between
sensitivity (true positive fraction) and speciﬁcity (false
positive fraction) and is an eﬀective method to evaluate
the performance of diagnostic tests. The calculation of
sensitivity and speciﬁcity depends on the threshold value
used to separate the two classes. As the thresholds gets
higher, speciﬁcity increases and sensitivity decreases;
conversely, lower threshold levels correspond to
decreased speciﬁcity and increased sensitivity [23,24]. The
Area Under Curve (AUC) is a value of diagnostic
accuracy that quantiﬁes the overall ability of the test to
discriminate between control and diseased individuals. It
ranges from totally non-informative (AUC = 0.5) to
perfect test (AUC = 1) [25,26]. Spearman rank
correlation was used to compare the DM1 miRNAs-score
with muscle strength measured by MRC megascore [21].
Kruskal Wallis non parametric assay was used to
compare the miR-133a and DM1 miRNAs-score levels
with MIRS score. All tests were performed 2-sided and a
p 6 0.05 was considered as statistically signiﬁcant. For
statistical analysis and heat map data visualization,
GraphPad Prism v.4.03 (GraphPad Software Inc.) and
Genesis 1.7.2 (Graz University of Technology, Institutefor Genomics and Bioinformatics) softwares were used,
respectively.3. Results
3.1. Identiﬁcation of diﬀerentially expressed miRNAs in
DM1 plasma
Plasma was derived from the peripheral blood of 36
consecutive DM1 patients and from 36 age and sex
matched controls (CTR), displaying no neuromuscular
disorders. As expected, most DM1 displayed myotonia,
cataract and loss of muscle strength (Table 1). Total
RNA was extracted from plasma samples and
microRNAs proﬁling was performed by multiplex
qPCR in small patient groups (DM1, n = 24 and CTR,
n = 26). Out of 381 miRNAs measured (Table S1), 113
were detectable (average Ct 6 30, highlighted in yellow
in Table S1) in at least one of the groups and 14 were
signiﬁcantly modulated at least 2-fold, either positively
or negatively (Fig. S1). Validation was performed by
miRNA single qPCR assays (no multiplexing) and was
extended to all recruited patients and CTR. Given the
existing controversy on the most precise normalization
method for circulating miRNAs [27], we decided to
use, alone or in combination, both an exogenous
spike-in normalizer (cel-miR-39) and the average of 2
stable endogenous miRNA normalizers (hsa-miR-106a
and hsa-miR-17) [22]. Thus, one miRNA was
considered as validated only if displayed signiﬁcant
diﬀerences after normalization with all of the following
references: (1) the average of the 3 normalizers (Fig. 1);
(2) cel-miR-39 values (Fig. S2A); (3) the average of
miR-106a and miR-17 (Fig. S2B). Using these stringent
normalization criteria, we found 9 signiﬁcantly
deregulated miRNAs in DM1 patients: miR-133a,
miR-193b, miR-191, miR-454, miR-574, miR-885-5p
and miR-886-3p were increased, while the levels of
CLUSTERING ANALYSIS
Fig. 2. Complete linkage clustering of miRNAs expression segregates DM1 from CTR samples. Each row represents a validated miRNA and each column
represents an individual. Data are normalized versus the average of three normalizers (cel-miR-39, hsa-miR-17 and hsa-miR-106a) and are expressed in
log2 scale. The color coding represents miRNAs expression, where red indicates an up-regulation and green a down-modulation.
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these 9 miRNAs, values obtained with the 3
normalization methods were very similar.
As expected, cluster analysis shows that the combination
of these values, with only few exceptions, discriminated
DM1 patients from CTR (Fig. 2).Fig. 3. miRNA-133a levels identify DM1 patients and correlate with muscle
segments among dots indicate median values for each group (****p < 0.000
discriminating between DM1 and CTR groups (AUC = 0.94, C.I. 0.88–1.00; p
between miRNA-133a fold change compared to CTR and muscle strength m
n = 36). (D) miR-133a data were divided according to MIRS score. Kruska
miR-133a values in subjects belonging to higher MIRS classes.3.2. miR-133a and DM1-miRNAs score accurately
discriminate the two populations and correlate with muscle
strength and MIRS class
To test the diﬀerentiating value of the identiﬁed
miRNAs, we determined miRNA speciﬁc cutoﬀ levelsstrength. (A) Dot plot of the miR-133a levels in DM1 and CTR. The
1). (B) ROC curve illustrating sensitivity/speciﬁcity of miRNA-133a in
< 0.0001; DM1 n = 36, CTR n = 36). (C) Spearman’s inverse correlation
easured by MRC megascore (r = 0.6; p < 0.0001; DM1 n = 36, CTR
l Wallis analysis identiﬁed a signiﬁcant (p < 0.0001) increase of median
Fig. 4. DM1-miRNAs score identiﬁes DM1 patients and correlates with muscle strength. A “DM1-miRNAs score” averaging the fold changes obtained
for all miRNAs was calculated (DM1 n = 36, CTR n = 36). (A) Dot plot of the DM1-miRNAs score in DM1 and CTR. The segments among dots indicate
median values for each group (****p < 0.0001). (B) ROC curve illustrating sensitivity/speciﬁcity of DM1-miRNAs score in discriminating between DM1
and CTR groups (AUC = 0.97, C.I. 0.94–1.00; p < 0.0001). (C) Spearman’s inverse correlation (r = 0.7; p < 0.0001) between DM1-miRNAs score and
muscle strength measured by MRC megascore. (D) DM1-miRNAs score data were divided according to MIRS score. Kruskal Wallis analysis identiﬁed a
signiﬁcant (p < 0.0001) increase of median DM1 miRNA-score values in subjects belonging to higher MIRS classes.
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curves (Fig. S3), and we found that miR-133a (Fig. 3A)
had the highest area under the curve (AUC = 0.94)
(Fig. 3B).
Moreover, we also tested whether combining the
values of all diﬀerentially expressed miRNA allowed even
better performances. To this aim, we calculated a
“DM1-miRNAs score” averaging the fold changes
obtained for all miRNAs. As expected, DM1-miRNAs
score values were signiﬁcantly diﬀerent for DM1 and
CTR groups (p < 0.0001, Fig. 4A). By analyzing the ROC
curve, the obtained AUC of 0.97 was further increased
compared to the one of miR-133a alone (Fig. 4B). Indeed,
by using a threshold score of 6.95, both sensitivity and
speciﬁcity of 91.7% for the identiﬁcation of DM1 patients
were achieved.
The low number of analyzed patients did not allow
stratiﬁcation and limited correlation analysis with
clinically relevant parameters. However, considering all
tested subjects, we identiﬁed a negative correlation of
both miR-133a values (Spearman r = 0.6, Fig. 3B) and
DM1-miRNAs score values (Spearman r = 0.7,Fig. 4C) with global muscle strength. Moreover, there
was a signiﬁcant increase of median miR-133a (Fig. 3D)
and DM1 miRNA-score values (Fig. 4D) in subjects
belonging to higher MIRS classes.
4. Discussion
Circulating miRNAs proﬁle has been found to
dynamically change in correlation with the pathological
state in many diseases such as cancer, myocardial
infarction, heart failure and Duchenne Muscular
Dystrophy [28–30].
In this study, we identiﬁed 9 deregulated miRNAs in the
plasma of DM1 patients. Particular attention was devoted
to the still controversial issue of data normalization,
adopting criteria that are at the same time stringent and
easily transferable to a possible diagnostic routine.
Interestingly, when cluster analysis was performed,
DM1 and control subjects segregated in diﬀerent classes,
albeit few exceptions were present. When considered as
potential biomarkers, each miRNAs displayed diﬀerent
sensitivity and speciﬁcity levels, with AUC values ranging
514 A. Perfetti et al. / Neuromuscular Disorders 24 (2014) 509–515from a minimum of 0.67 for miR-27b, to a maximum of
0.94 for miRNA-133a. Indeed, miRNA-133a, expressed
in skeletal and cardiac muscles, was increased in DM1
plasmas compared to controls, and, considered alone, it
allowed to distinguish DM1 patients almost as eﬃciently
as the global signature of 9 miRNAs. MiR-133a plasma
levels increase is unlikely due to passive release from
damaged myoﬁbers. Indeed, other equally or more
abundant myomiRs such as miR-1, and miR-133b [11],
did not display signiﬁcant alterations of plasma levels in
DM1 patients, as reported for Duchenne Muscle
Dystrophy instead [13–15]. Interestingly, while myomiR
levels are not modulated in DM1 skeletal muscle
biopsies, their intracellular distribution is aberrant [11],
possibly leading also to increased extracellular release of
miR-133a, with unknown selection mechanisms. Another
evidence is that DM1-miRNA levels in the plasma do not
simply reﬂect passive release due to tissue damage is the
fact miR-27b is down-modulated in DM1 patients; thus,
either miR-27b release in the extracellular space is
decreased or cell re-uptake of miR-27b is increased in
DM1 patients.
Another muscle-related DM1-miRNA is miR-885, that
has been associated to bovine muscle type-speciﬁc tissue
formation and maintenance [31]. The other identiﬁed
plasma DM1-miRNAs are not muscle speciﬁc/enriched.
Indeed, miR-140-3p is highly expressed in the cartilage
[32] and miR-27b controls fat deposition in dystrophic
skeletal muscle by regulating ﬁbro-adipogenic precursor
diﬀerentiation [33]. Intriguingly, we previously found that
miR-193b is down-regulated in skeletal muscle biopsies of
DM2 patients [9]. It remains to be determined if this also
observed in DM1. Finally, miR-886 is not even properly
a miRNA, since it has been found to be identical to a
fragment of Vault RNA 2 (VTRNA2) [34].
Given the fact that DM1 is a multisystemic disorder, it is
possible that the tissue of origin of many DM1-miRNAs
might not be skeletal muscles. In this respect, circulating
miRNAs hold the potential to reﬂect the overall clinical
state of the patient, rather than that of a speciﬁc tissue or
organ. This seems particularly important given that DM1
is a multisystemic disease, with involvement of the heart,
the eye, the central nervous system and of the insulin
pathway [1].
The identiﬁcation of new disease biomarkers is
particularly important to monitor DM1 progression and
eﬀectiveness of new drug treatments. In this respect, a
minimally invasive, relatively simple analytical assay is
particularly desirable and currently not available for
DM1 patient care. We identiﬁed one speciﬁc miRNA,
miR-133a, and devised a DM1-miRNAs score that
both correlate with muscle strength measurement and
increased in patients with higher MIRS score, potentially
reﬂecting disease severity. One interesting question that
remains to be elucidated is whether the identiﬁed
miRNAs are deregulated also in DM type 2 and
other muscular dystrophies. Indeed, increased levels ofmiR-133a and miR-193b have been observed also in
Duchenne Muscle Dystrophy [13–15]. Moreover, in a
longitudinal study, it will be necessary to test miR-133a
and DM1-miRNAs score changes over time during
disease evolution.
In conclusion, despite the preliminary character of our
observations, the results provide suﬃcient rationale for a
larger conﬁrmation study.
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